NCT02791334 - A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

May 22, 2020

Study Completion Date

June 27, 2024

Conditions

Solid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsCutaneous MelanomaPancreatic CancerBreast Cancer (HR+HER2-)

Interventions

DRUG

LY3300054

Administered IV

DRUG

Ramucirumab

Administered IV

DRUG

Abemaciclib

Administered orally

DRUG

Merestinib

Administered orally

DRUG

LY3321367

Administered IV

Trial Locations (14)

1200

Cliniques Universitaires Saint-Luc, Brussels

2650

Universitair Ziekenhuis Antwerpen, Edegem

10048

National Taiwan University Hospital, Taipei

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28050

Hospital Madrid Norte Sanchinarro, Madrid

33076

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux

37203

Tennessee Oncology PLLC, Nashville

70403

National Cheng Kung University Hospital, Tainan City

77030

University of Texas MD Anderson Cancer Center, Houston

78229

The START Center for Cancer Care, San Antonio

94805

Gustave Roussy, Villejuif

M5TY 2M9

Princess Margaret Hospital, Toronto

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY